Anuja U Chattopadhyay

US Patent:

8236489, Aug 7, 2012

Filed:

Nov 19, 2009

Appl. No.:

12/622022

Inventors:

Michael Gabrin - Pittsburgh PA, US
Stacey Brower - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Holly Gallion - Pittsburgh PA, US
Payal Nanavati - Pittsburgh PA, US
Shara Dawn Rice - Pittsburgh PA, US
Anuja Chattopadhyay - Pittsburgh PA, US

Assignee:

Precision Therapeutics, Inc. - Pittsburgh PA

International Classification:

G01N 33/574
G01N 33/577
C12N 5/02
C12N 5/06
C12N 5/09
C12Q 1/00

US Classification:

435 4, 435 723, 435374, 435375, 435379, 435381, 435383

Abstract:

The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.

US Patent:

20080085519, Apr 10, 2008

Filed:

Apr 23, 2007

Appl. No.:

11/785984

Inventors:

Michael Gabrin - Pittsburgh PA, US
Stacey Brower - Pttsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Holly Gallion - Pittsburgh PA, US
Payal Nanavati - Pittsburgh PA, US
Shara Rice - Pittsburgh PA, US
Anuja Chattopadhyay - Pittsburgh PA, US

International Classification:

G01N 33/574
C12N 5/06
C12Q 1/02
C12Q 1/68

US Classification:

435006000, 435029000, 435375000, 435394000, 435007230

Abstract:

The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.

US Patent:

20120329086, Dec 27, 2012

Filed:

Jul 5, 2012

Appl. No.:

13/542000

Inventors:

Michael Gabrin - Pittsburgh PA, US
Stacey Brower - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Holly Gallion - Pittsburgh PA, US
Payal Nanavati - Pittsburgh PA, US
Shara Dawn Rice - Pittsburgh PA, US
Anuja Chattopadhyay - Pittsburgh PA, US

Assignee:

Precision Therapeutics, Inc. - Pittsburgh PA

International Classification:

C12Q 1/18

US Classification:

435 32

Abstract:

The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.